Knowledge Center

Unifi Announces New Share Repurchase Program

On October 31, Unifi, Inc. (UFI) announced that the company’s Board of Directors authorized a new stock repurchase program. The Board of Directors terminated the previous program, which had been in place since April 2014. The new program authorizes management to repurchase up to $50 million of the company’s common stock. Sonal detected the event […]

Read more...

NeoGenomics to Acquire Genoptix

NeoGenomics, Inc. (NEO) announced on October 23 that the company has entered into a definitive agreement to acquire Genoptix, Inc. NeoGenomics will pay $125 million in cash plus 1 million shares of NeoGenomics common stock according to the agreement. Genoptix is a leading clinical oncology laboratory, and NeoGenomics is the leading provider of cancer-focused genetic […]

Read more...

Ameris Bancorp Announces New Stock Repurchase Program

On October 25, Ameris Bancorp (ABCB) announced that its Board of Directors authorized a new share repurchase program. Under this program, Ameris Bancorp can repurchase up to $100 million in common shares over the next 12 months. Ameris Bancorp is a bank holding company with branch locations in Georgia, Florida, Alabama, and South Carolina.   […]

Read more...

Canopy Growth Corp. to Buy Ebbu’s Hemp Research Assets

Canopy Growth Corporation (CPC) announced on October 15 that the company would purchase the intellectual property and assets of Ebbu Inc for CAD 25 million plus 6.2 million shares. Canopy Growth is a Canadian pot company, and Ebbu is a Colorado-based hemp research company. CPC hopes to reduce its production costs by implementing technology developed […]

Read more...

September 2018 Scorecard

The September 2018 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide

Read more...

Paratek Receives FDA Approval of NUZYRA to Treat Bacterial Pneumonia and Skin Infections

On October 2, Paratek Pharmaceuticals, Inc. (PRTK) announced that the company received FDA approval of NUZYRA™ (omadacycline) to treat community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). NUZYRA is an antibiotic that can be administered either orally or through a once-daily IV treatment. Paratek plans to have the drug available in […]

Read more...

Seattle Genetics and Takeda Pharmaceuticals Report Positive Topline Phase 3 Clinical Trial Results

On October 1, Seattle Genetics, Inc. (SGEN) and Takeda Pharmaceutical Company Limited (TSE) reported results from their phase 3 clinical trial of ECELON-2. The trial demonstrated a statistically significant improvement in progression-free survival for patients using their drug Adcentris in combination with chemotherapy when compared to chemotherapy alone. It is the first randomized Phase 3 […]

Read more...

Kirkland’s Announces New Share Repurchase Program

On September 24, Kirkland’s, Inc. (KIRK) announced that its Board of Directors authorized a new share repurchase program. The new program allows the company to repurchase up to $10 million worth of common shares. Kirkland’s still has $2.9 million available from its previous $10 million share repurchase program.   Sonal alerted subscribers of the event […]

Read more...

Akcea and Ionis Announce Positive Phase 2 Clinical Trial Results

Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (IONS), announced positive topline clinical trial results on September 24. The Phase 2 clinical trial is studying the effect of AKCEA-APO(a)-LRx on patients with established cardiovascular disease and elevated levels of lipoprotein(a), known as Lp(a). The goal of the Phase 2 clinical study was to […]

Read more...

Progenics Pharmaceuticals Reports Top Line Phase 3 Clinical Trial Results

On September 13, Progenics Pharmaceutical, Inc. (PGNX) reported Phase 3 clinical trial results from its study of 1404, the company’s prostate specific membrane antigen (PSMA). It is a targeted small molecule SPECT/CT imaging agent designed to visualize prostate cancer. The results met one of the co-primary endpoints of identifying patients without clinically significant prostate cancer. […]

Read more...